Ganglioneuroblastoma, nodular
Clinical trials for Ganglioneuroblastoma, nodular explained in plain language.
Never miss a new study
Get alerted when new Ganglioneuroblastoma, nodular trials appear
Sign up with your email to follow new studies for Ganglioneuroblastoma, nodular, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to keep high-risk neuroblastoma from coming back
Disease control OngoingThis study tests whether adding two chemotherapy drugs (irinotecan and temozolomide) to the standard immunotherapy regimen (dinutuximab, GM-CSF, isotretinoin) can safely prevent high-risk neuroblastoma from returning after intensive initial therapy. About 41 children and young ad…
Matched conditions: GANGLIONEUROBLASTOMA, NODULAR
Phase 2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New scan could spot childhood cancer more clearly
Diagnosis CancelledThis study tests whether a new type of PET scan (18F-MFBG) can detect neuroblastoma tumors as accurately as the current standard scan (123I-MIBG). About 84 children and adults with newly diagnosed, high-risk neuroblastoma will receive both scans to compare results. If the new sca…
Matched conditions: GANGLIONEUROBLASTOMA, NODULAR
Phase 2 • Sponsor: Children's Oncology Group • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Could a 4-Hour infusion replace 20 hours for neuroblastoma kids?
Symptom relief OngoingThis study tests if giving the drug dinutuximab over 4 hours or less is safe and practical for children with high-risk neuroblastoma. Currently, standard infusions take 10-20 hours and require a hospital stay. The goal is to see if a shorter infusion can be used in an outpatient …
Matched conditions: GANGLIONEUROBLASTOMA, NODULAR
Phase 2 • Sponsor: Children's Hospital Los Angeles • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC